Home > Blog > Advancing dose escalation strategies with bayesian modeling

1 min read

Advancing Dose Escalation Strategies with Bayesian Modeling

Oncology

Learn how our biostatistics and strategic consulting teams collaborated with our biotechnology sponsor to advance dose escalation strategies through Bayesian modeling in a Phase 1/2 study for a novel oncology compound. Our efforts led to real-time, data-driven decision making and reduced trial duration while maintaining patient safety.

A biotechnology sponsor developing an oncology therapy engaged us to support the design and execution of a multicenter, open-label Phase 1/2 dose escalation and expansion study. The sponsor aimed to shorten traditional dose escalation timelines without compromising patient safety, moving beyond conventional 3+3 design limitations.

In this case study, learn how Veristat experts were able to work with the sponsor to solve challenges across:

  • Bayesian CRM implementation

  • Real-time decision support

  • Operational complexity management

  • Safety review committee participation

  • Multi-cycle DLT integration

  • Strategic consultative planning

Download our complete case study "Advancing Dose Escalation Strategies with Bayesian Modeling"

DOWNLOAD

 
Contact us today to learn how we can help:
LET'S TALK

2 min read

Connect with Veristat at Bio International Convention 2026

Jun 15, 2026  Veristat Events

June 22-25, 2026 – San Diego, CA

🌎 Bringing the Global Biopharma Community Together

We’re delighted to be attending...

2 min read

Connect with Veristat at DIA 2026

Jun 5, 2026  Veristat Events

June 14-18, 2026 – Philadelphia, PA

Veristat is excited to join industry leaders and innovators at the DIA 2026 Global...